Oral Administration of the carboxylic acid ester prodrug NHC SN_9 protects mice from lethal Orthopoxvirus challenge: Implications for the Treatment of Monkeypox
Siniavin, A.; Gushchin, V.; Shastina, N.; Darnotuk, E.; Luyksaar, S.; Dolzhikova, I.; Inshakova, A.; Zigangirova, N.; Gintsburg, A.; Logunov, D.
Show abstract
The global resurgence of monkeypox (Mpox) since 2022 has highlighted an urgent need for effective antiviral therapeutics against orthopoxvirus infections. While vaccines provide prophylactic protection, therapeutic options remain limited, particularly for immunocompromised individuals. Previously, we demonstrated potent antiviral activity of N4-hydroxycytidine (NHC) analogs against coronaviruses, including SARS-CoV-2. In the present study, we evaluated the antiviral efficacy of one such analog, NHC conjugate with phenylpropionic acid - SN_9, against orthopoxviruses using Vaccinia virus (VACV) as a model. SN_9 demonstrated superior in vitro antiviral activity compared with EIDD-2801 (molnupiravir), significantly inhibiting VACV replication. In vivo, oral administration of SN_9 provided substantial protection in murine models of orthopoxvirus infection, achieving 90% survival in a sublethal infection model and 70% survival in a lethal challenge model. Animals receiving treatment showed a reduction in disease severity and faster weight recovery. Given the high genetic and antigenic similarity among orthopoxviruses, including VACV, variola virus, and monkeypox virus (MPXV), these findings suggest that SN_9 represents a promising candidate for the treatment and prophylaxis of Mpox.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Metal Coordinating Inhibitors of Rift Valley Fever virus Replication 96%
- In silico pharmacological analysis of Tinospora cordifolia compounds targeting African swine fever virus B175L 94%
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants 93%
Similar papers in this journal
- Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell 95%
- In Vitro Activity of Itraconazole Against SARS-CoV-2 95%
- Repurposing of the antibiotic nitroxoline for the treatment of mpox 93%
Similar papers in this journal
- Inhibitors of anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0/G1 phase 94%
- Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice 94%
- Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.